Abstract
The mouse strain MRL/MpJ is prone to spontaneously develop autoimmune pancreatitis (AIP). To elucidate the genetic control towards the development of the phenotype and to characterize contributions of immunocompetent cell types, MRL/MpJ mice were interbred with three additional strains (BXD2/TYJ, NZM2410/J, CAST/EIJ) for four generations in an advanced intercross line. Cellular phenotypes were determined by flow cytometric quantification of splenic leukocytes and complemented by the histopathological evaluation of pancreatic lesions. An Illumina SNP array was used for genotyping. QTL analyses were performed with the R implementation of HAPPY. Out of 41 leukocyte subpopulations (B cells, T cells and dendritic cells), only three were significantly associated with AIP: While CD4+/CD44high memory T cells and CD4+/CD69+ T helper (Th) cells correlated positively with the disease, the cytotoxic T cell phenotype CD8+/CD44low showed a negative correlation. A QTL for AIP on chromosome 2 overlapped with QTLs for CD4+/CD44high and CD8+/CD44high memory T cells, FoxP3+/CD4+ and FoxP3+/CD8+ regulatory T cells (Tregs), and CD8+/CD69+ cytotoxic T cells. On chromosome 6, overlapping QTLs for AIP and CD4+/IL17+ Th17 cells and again FoxP3+/CD8+ Tregs were observed. In conclusion, CD4+/CD44high memory T cells are the only leukocyte subtype that could be linked to AIP both by correlation studies and from observed overlapping QTL. The potential role of this cell type in the pathogenesis of AIP warrants further investigations.
Introduction
Autoimmune pancreatitis (AIP) represents a rare form of chronic pancreatitis that is nevertheless clinically important for two reasons: First, AIP is a differential diagnosis of pancreatic cancer, a devastating disease where radical surgery as the only curative therapy is applicable in a minority of patients only. Secondly, therapy of AIP differs not only from the therapy of pancreatic cancer, but also from the treatment of other, more common forms of chronic pancreatitis: AIP is highly sensitive to immunosuppressants and can usually be successfully treated with steroids (reviewed in [1]). Hence, there is need for an early and reliable diagnostics of AIP, which remains challenging despite the availability of diagnostic algorithms that consider radiological, serological and histological criteria [2].
To a large extent, improvement of AIP diagnostics (and therapy) is currently limited by the incomplete knowledge of the pathogenesis of the disease. The initial triggering mechanisms are largely unknown, and the specific contribution of individual autoantigens (mainly digestive enzymes of pancreatic acinar cells, but also proteins from pancreatic duct cells [1,3,4]) is under debate.
Recent concepts distinguish between two subtypes of AIP. The pathognomonic finding in AIP of subtype 1 is the abundant infiltration of pancreatic tissue with lymphocytes and IgG4+ plasma cells. This form of AIP is now considered as the pancreatic manifestation of a multi-organ disease, which has recently been named IgG4-related disease. In AIP subtype 2, the typical histopathologic pattern includes granulocytic epithelial lesions, while IgG4+ plasma cells are lacking [5,6]. Both forms of AIP are characterized by a progressive replacement of pancreatic tissue by connective tissue (fibrosis), formation of inflammatory pseudotumors, and clinically by frequent presentation with obstructive jaundice [1].
AIP shares with other autoimmune diseases key features such as genetic predisposition (outlined below), detectability of autoantibodies and the presence of autoreactive T cells [1]. The observation that depletion of B cells with anti-CD20 antibodies is an effective therapy for AIP [7] has demonstrated a crucial involvement of these immune cells in the pathogenesis of the disease. In addition, a growing body of evidence implicates different subsets of T cells in the progression of AIP. Thus, both T helper (Th) 1 and Th2 immune responses have been described to occur in AIP [1,8–10], and the possibility that the Th1/Th2 balance may shift dynamically between early and advanced AIP has been suggested [1]. Own studies in MRL/MpJ mice, a model of spontaneous AIP [11], have shown a key role of effector T cells in the development of the disease, but also implicated regulatory T cells (Tregs) in the suppression of AIP progression [12,13]. In AIP patients, increased numbers of Tregs have been detected both in pancreatic tissue [10] and peripheral blood [14]. Together, these observations suggest a complex interplay between components of cellular and humoral autoimmunity in AIP, the details of which still remain to be elucidated.
Multifactorial diseases, such as autoimmune and chronic inflammatory disorders, are considered to be influenced both by environmental and genetic factors [15–18]. With respect to the genetic basis of AIP, genome-wide association studies are hampered by the lack of large cohorts of patients. Nevertheless, some genetic risk factors of human AIP have already been proposed: In a Japanese population, the HLA serotypes DRB1*0405 and DQB1*0401 were found to increase the susceptibility to AIP [19]. In patients from Korea, a mutation of DQbeta1 (substitution of aspartic acid at position 57) was identified as a key genetic factor for relapse of AIP [20]. Furthermore, single-nucleotide polymorphisms (SNPs) in five non-HLA genes, cytotoxic T lymphocyte-associated antigen 4 (CTLA4) [21,22], tumor necrosis factor-α (TNF-α) [22], cationic trypsinogen (PRSS1) [23], Fc receptor-like 3 (FCRL3) [24], and KCNA3 (potassium voltage-gated channel, shaker-related subfamily) [25] have been linked to AIP.
Given the problems of obtaining large sizes of human samples, studies in animal models of AIP may provide valuable additional insights into the genetic basis of the disease. We have previously established an advanced intercross line originating from MRL/MpJ parental mice and three other mouse strains: CAST/EIJ (healthy controls), BXD2/TYJ (susceptible to collagen-induced arthritis) and NZM2410/J (a model of Lupus erythematodes) [26]. The idea beyond this concept was to map both general autoimmune disease-associated loci and AIP-specific quantitative traits. Therefore, generation 4 of outbread intercross mice was characterized phenotypically by scoring histopathological changes of the pancreas and genotyped employing SNP arrays. By this approach, five quantitative trait loci (QTL), located on chromosomes 2, 4 (n = 2), 5 and 6, were mapped [26]. Similarly, we identified QTLs controlling arthritis and skin inflammation [27,28]. Taking sex as a covariate, we have now used the same approach to study genomic loci that control immune cell phenotypes in the spleen and to determine their overlap with the QTLs for AIP. Out of several leukocyte subtypes, only CD4+/CD44high memory T cells where not only controlled by such an overlapping QTL, but also showed a significant correlation of their relative frequency with the appearance of AIP.
Materials and Methods
Animal Model and Experimental AIP
The establishment of the 4-way autoimmunity advanced intercross line has been described before [26]. Briefly, MRL/MpJ, NZM2410/J, BXD2/TyJ and CAST/EiJ parental mouse strains were intercrossed at an equal strain and sex distribution. To maintain an equal distribution of original strains in subsequent generations, parental origin of offspring mice of the predecessor generation was considered. For each generation of mice, at least 50 breeding pairs were used as parentals. As previously described, MRL/MpJ mice, but no individuals of the other parental strains, developed AIP in an age and gender specific manner [26,29].
Development of spontaneous AIP in parental strains and in intercross generation 4 (156 males and 175 females) was assessed in 6-months-old mice by evaluating the severity of pancreatic lesions. Therefore, paraffin-embedded pancreatic sections were stained with hematoxylin and eosin (H&E), applying standard protocols. Pathological changes were graded on a semi-quantitative scale from 0 to 4 [26]. The stages were defined as follows: 0, no pathological changes; 1, minimal infiltration of periductal tissue with mononuclear cells but no parenchymal destruction; 2, moderate periductal infiltration with mononuclear cells associated with beginning parenchymal destruction; 3, severe periductal inflammation and/or more extended parenchymal destruction; 4, diffuse mononuclear cell infiltrates, destruction of acini and (partial) replacement by adipose tissue. All samples were assessed by two independent investigators and blinded before evaluation. AIP stages were determined by microscopic analysis of at least two tissue sections per sample. Mice with pancreatic lesions that scored ≥ 2 were defined as positive for AIP.
Animals were kept under specific pathogen-free conditions at a 12 h light/dark cycle with food and water ad libitum. All procedures were performed with adherence to the EU Directive 2010/63/EU for animal experiments and approved by the local governmental administrations (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern).
Immunohistochemical Analysis
Cryostat sections of pancreatic tissue (6 μm) were fixed by incubation in ice-cold methanol for 1 min at 4°C and washed three times with PBS. Subsequently, they were stained using the Vectastain ABC staining kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer’s instructions. For the detection of CD4 and CD44, mouse-specific primary rat antibodies were employed (anti-CD4, Immunotools, Friesoythe, Germany and anti-CD44, eBioscience, San Diego, CA, USA, respectively). The sections were counterstained with hemalaun and examined by light microscopy (Axioskop 40, Zeiss, Oberkochen, Germany).
Analysis of Leukocyte Subtypes by Flow Cytometry
Splenocytes were isolated from the spleen of G4 mice using a cell strainer (70 μm). Red blood cells were lysed applying RBC lysis buffer (eBioscience) according to the manufacturer’s instructions. After washing and centrifugation steps, 1x106 cells per stain were subjected to subsequent analysis. Prior to staining, Fc receptors on splenocytes were blocked by pre-incubation with anti-CD16/CD32 antibodies (BD Biosciences, Heidelberg, Germany) for 5–10 minutes on ice. Surface staining was performed by incubating the cells with fluorochrome-conjugated specific antibodies (listed in the supplement, S1 Table) for at least 20 min in dark on ice. After washing and centrifugation steps, stained cells were fixed with 1% paraformaldehyde for 10–20 min at 4°C and subjected to flow cytometry.
For staining of intracellular cytokines, single cell suspensions of splenocytes were fixed in 4% paraformaldehyde for 10–20 min at 4°C and permeabilized employing Saponin (0.3%; Sigma-Aldrich, Deisenhofen, Germany) for 10 min. Afterwards, optimized concentrations of fluorochrome-conjugated anti-cytokine antibodies were applied at 4°C for 30 min in the dark, followed by washing steps and flow cytometry.
FACS analysis was performed using a FACSCalibur cytometer (BD Biosciences). 10,000 events were measured for each sample, and the data were processed employing the BD CellQuest software. In total, 41 different subsets of leukocytes were analyzed. Investigations included B cells (n = 6 phenotypes); cytotoxic T cells (n = 8 subtypes); CD4/CD8 double-positive T cells; Th1, Th2 and Th17 lymphocytes as well as otherwise defined subsets of Th cells (n = 10); Tregs (n = 2); further phenotypes of T cells (n = 4); conventional dendritic cells (conventional DCs; n = 3) and plasmacytoid DCs (PD; n = 4). With the following exceptions, all FACS antibodies were obtained from BD Biosciences: anti-CD4 and anti-CD45R (B220)—Immunotools (Friesoythe, Germany), anti-MHC class II, anti-PDCA-1 and anti-FoxP3 –eBioscience, and anti-CD8 –Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Details regarding marker combinations and the corresponding leukocyte subpopulations are given in Table 1. The table also indicates the averaged results for each phenotype, obtained from the analysis of 331 G4 mice. Data are expressed as relative frequency of the investigated leukocyte subset, with 100% corresponding to the total number of splenocytes. Representative dot plots of the experimental data are shown in the supplement (S1 Fig).
Table 1. Summary of immune cell phenotypes of mice splenocytes detected by flow cytometry.
Cell Type | Marker | Mean ± SD | ||
---|---|---|---|---|
B cells | CD19+/CD69- | 36.81 ± 11.13 | ||
CD19+/CD69+ | 0.29 ± 0.21 | |||
CD19+/CD86- | 38.65 ± 9.78 | |||
CD19+/CD86+ | 0.41 ± 0.36 | |||
CD19+/ MHC II- | 5.15 ± 5.7 | |||
CD19+/ MHC II+ | 32.51 ± 11.6 | |||
T cells | CD3+/CD8+ | 8.3 ± 4.06 | ||
CD8+/CD44low | 4.2 ± 3.12 | |||
CD8+/CD44high | 4.6 ± 3.47 | |||
cytotoxic | CD8+/CD62L- | 2.5 ± 2.38 | ||
T cells | CD8+/CD62L+ | 6.07 ± 3.81 | ||
CD8+/CD69- | 8 ± 4.59 | |||
CD8+/CD69+ | 0.38 ± 0.37 | |||
CD8+/FoxP3- | 8.36 ± 4.56 | |||
DP T cells | CD4+/CD8+ | 0.57 ± 0.38 | ||
Th 1 | CD4+/IFNγ+ | 0.48 ± 0.6 | ||
Th 2 | CD4+/IL4+ | 0.21 ± 0.21 | ||
Th 17 | CD4+/IL17+ | 0.29 ± 0.27 | ||
CD3+/CD4+ | 15.5 ± 5.59 | |||
CD4+/CD8- | 15.66 ± 5.6 | |||
T helper | CD4+/CD69- | 16.4 ± 5.33 | ||
cells | CD4+/CD69+ | 0.33 ± 0.68 | ||
others | CD4+/CD44low | 4.54 ± 3.44 | ||
CD4+/CD44high | 12.63 ± 4.34 | |||
CD4+/CD62L- | 9.39 ± 3.48 | |||
CD4+/CD62L+ | 7.54 ± 4.65 | |||
CD4+/FoxP3- | 17.64 ± 6.93 | |||
CD4+/IFNγ- | 17.58 ± 6.27 | |||
Tregs | CD4+/FoxP3+ | 0.41 ± 0.38 | ||
CD8+/FoxP3+ | 0.14 ± 0.14 | |||
CD3+/CD4- | 9.81 ± 4.13 | |||
others | CD3+/CD8- | 17.01 ± 5.75 | ||
CD3+/B220- | 22.91 ± 8.6 | |||
CD3+/B220+ | 2.32 ± 1.01 | |||
DCs | PDCA1+/CD86- | 3.51 ± 3.52 | ||
PD cells | PDCA1+/CD86+ | 0.46 ± 0.54 | ||
PDCA1+/CD11c- | 2.33 ± 2.4 | |||
PDCA1+/CD11c+ | 0.76 ± 0.46 | |||
CD11c+/CD86- | 2.43 ± 1.21 | |||
cDCs | CD11c+/CD86+ | 0.32 ± 0.32 | ||
CD11c+/PDCA1- | 1.95 ± 1.01 |
Correlation Analysis
Correlations between AIP appearance and sex, as well as between AIP and leukocyte subpopulations, were analyzed using Spearman’s correlation coefficient (Spearman’s rho). Significance of correlations was calculated using a correlation test in R. Correction for multiple testing was done by controlling the false discovery rate using the Benjamini-Hochberg approach.
QTL Mapping
331 G4 mice were genotyped by a set of 1400 single nucleotide polymorphisms (SNPs) using an Illumina murine HD array (Illumina, California, USA). To provide QTL coordinates, NCBI Build 36 was used. Genotype/phenotype correlation was performed with the R package of HAPPY [30] in version 2.3 beta on Debian Linux [31]. The default parameters were applied, including four generations. For the analysis of the AIP phenotype binomial stages (AIP stages <2 and ≥2) were used and for the immune phenotypes relative frequencies. Using sex as covariate, the data of all chromosomes were analyzed together in an additive model, and tested positively against 1000 permutations for global significance (p<0.05). The flanking regions of QTLs were determined manually by a drop of 1.5 of the-log p value to both sides of the peak.
Results
Pancreatic Histopathology and Immune Cell Phenotypes of G4 Mice
Generation 4 of the 4-way autoimmune-prone intercross mouse line was employed, at an age of 6 months, to assess pancreatic histopathology and relative frequencies of different leukocyte subsets in the spleen. Therefore, 331 mice (156 females and 175 males) were included into the investigations. The mice represent a subset of the previously analyzed 351 animals [26], which was chosen based on the availability of flow cytometry data. Scoring of AIP-typical pancreatic lesions, such as presence of lymphocytic foci and parenchymal destruction, revealed an AIP stage 2 or 3 in 44 mice (32 females and 12 males). Stage 4 was not detected, but has been observed in mice of the advanced intercross line outside of this study (R.J., unpublished data). These numbers correspond to 18.3% of the females but only 7.7% of the males (13.3% of all mice). Details are given in Table 2. Exemplary tissue stains are shown in Fig 1.
Table 2. Pancreatic histopathology.
Gender | Number | AIP stage | AIP stage | |||
---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 2 + 3 (%) | ||
Female | 175 | 49 | 94 | 31 | 1 | 18.3 |
Male | 156 | 77 | 67 | 11 | 1 | 7.7 |
Both | 331 | 126 | 161 | 42 | 2 | 13.3 |
The data are in line with our previous report [26], indicating that the 331 mice are representative of the entire cohort. They are also in agreement with the fact that AIP of the parental MRL/MpJ strain is largely restricted to females (at an age of at least 6 months) [11,29]. Gender dependency of AIP was also confirmed by correlation analysis (Spearman's rho = -0.16; p = 0.0090).
To study immune cell phenotypes in the context of AIP, splenocytes were phenotyped employing flow cytometry. We focused on 41 subsets of leukocytes (B cells, T cells and DCs), covering a large range of immunocompetent cells that have been implicated in the pathogenesis of various autoimmune diseases [32,33]. Special attention was paid to B cells, cytotoxic and helper T cells, Tregs and DCs. Table 1 in the Materials and methods section shows the relative frequencies of all these leukocyte subtypes as averaged values of the 331 G4 mice.
Correlations between AIP and Leukocyte Abundance
We next studied correlations between appearance of AIP and the relative frequencies of the 41 leukocyte subsets (Table 3).
Table 3. Significant correlations between AIP incidence and lymphocyte cell types, using Spearman’s correlation coefficient.
Subpopulation | Cell type | Spearman'srho | p value | Corrected p value |
---|---|---|---|---|
cytotoxic T cells | CD8+/CD44low | -0.16 | 0.0023 | <0.05 |
cytotoxic T cells | CD8+/CD69+ | 0.10 | 0.0498 | >0.05 |
T helper cells | CD4+/CD44low | -0.15 | 0.0053 | >0.05 |
T helper cells | CD4+/CD62L- | 0.12 | 0.0245 | >0.05 |
T helper cells | CD4+/CD69+ | 0.16 | 0.0030 | <0.05 |
T helper cells | CD4+/CD44high | 0.19 | 0.0003 | <0.05 |
A significant correlation (corrected p<0.05) was found for three populations of lymphocytes: activated Th cells (CD4+/CD69+), CD4+/CD44high memory T cells, and cytotoxic T cells of the phenotype CD8+/CD44low. While the first two leukocyte subsets were positively correlated with the disease, CD8+/CD44low cells displayed a negative correlation. For three further lymphocyte populations, p values <0.05 were determined only prior to correction for multiple testing. These cell types are activated cytotoxic T cells (CD8+/CD69+; positive correlation), and Th cells with the phenotypes CD4+/CD62L- (positive correlation) and CD4+/CD44low (negative correlation).
QTL Analysis
We have previously employed Illumina murine HD arrays to genotype 351 G4 mice of the 4-way autoimmune-prone intercross mouse line [26]. Here, we have re-analyzed the data subset of the 331 phenotyped mice (see above) to perform QTL analyses with sex as covariate. As shown in Table 4, a total of four QTLs could be mapped to the chromosomes 2, 4 and 6 (global p<0.05). The–log10(p) values varied from 4.2 to 5.5. To avoid any confusion with the previously identified QTLs, these new QTLs were termed AIP s1-s4. The mean confidence interval (CI) of each QTL was roughly 19 Mb.
Table 4. Significant QTLs found for AIP (1000 permutations; global p value <0.05).
QTL | Chromo-some | Peak position (Mbp) | CI (Mbp) | -log10(p) |
---|---|---|---|---|
AIP s1 | 2 | 59.9 | 56.4–73.3 | 4.23 |
AIP s2 | 4 | 82.8 | 79.3–101.1 | 4.61 |
AIP s3 | 6 | 104.8 | 94–106.3 | 4.31 |
AIP s4 | 6 | 116.7 | 109.9–136.3 | 5.54 |
Next, the same genotyping data subset was used to determine QTLs of all 41 leukocyte subpopulations (Table 5; S2 Table). Most significant QTLs (global p<0.05) were found for B cells (n = 80), T helper cells (n = 68) and cytotoxic T cells (n = 59). For conventional and plasmacytoid DCs, 8 and 7 QTLs, respectively, could be mapped, while for Tregs 25 loci were detected. Only 4 leukocyte subsets (CD19+/CD86+, CD8+/CD62L-, CD4+/CD69+ and PDCA1+/CD11c- cells) were not influenced by any QTL, whereas for CD19+/CD69-, CD19+/MHC II- and CD8+/CD69+ lymphocytes more than 20 QTLs were discovered. The mean CI of each QTL was about 13.6 Mb. -log10(p) values varied from 3.8 to 32.5 (S2 Table). QTLs were located on all chromosomes, but most were found on chromosomes 2, 6, 7, 9, 12 and 20 (Table 5). For B cells, most QTLs were mapped on chromosomes 8 and 9, for cytotoxic T cells on chromosome 20 and for T helper cells on chromosome 17 (Table 5).
Table 5. Number of significant QTLs found for leukocyte cell types (1000 permutations; global p value <0.05) on each chromosome.
Cell Type | Marker | Chromosome | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |||||
B cells | CD19+/CD69- | 2 | 3 | 1 | 3 | 4 | 4 | 3 | 3 | 1 | 2 | |||||||||||||
CD19+/CD69+ | 2 | 2 | 2 | 6 | ||||||||||||||||||||
CD19+/CD86- | 3 | 2 | 1 | 3 | 1 | 2 | ||||||||||||||||||
CD19+/CD86+ | ||||||||||||||||||||||||
CD19+/ MHC II- | 2 | 1 | 1 | 1 | ||||||||||||||||||||
CD19+/ MHC II+ | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 2 | 2 | |||||||||||
T cells | CD3+/CD8+ | 1 | 3 | 3 | ||||||||||||||||||||
CD8+/CD44low | 1 | 2 | 1 | 4 | 3 | |||||||||||||||||||
CD8+/CD44high | 2 | |||||||||||||||||||||||
cytotoxic | CD8+/CD62L- | |||||||||||||||||||||||
T cells | CD8+/CD62L+ | 1 | 1 | 1 | 1 | 3 | ||||||||||||||||||
CD8+/CD69- | 1 | |||||||||||||||||||||||
CD8+/CD69+ | 2 | 4 | 2 | 3 | 3 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | |||||||||||
CD8+/FoxP3- | 1 | 1 | 1 | 2 | ||||||||||||||||||||
DP T cells | CD4+/CD8+ | 1 | 1 | 1 | 1 | |||||||||||||||||||
Th 1 | CD4+/IFNγ+ | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | |||||||||||||||
Th 2 | CD4+/IL4+ | 1 | 1 | 1 | 1 | |||||||||||||||||||
Th 17 | CD4+/IL17+ | 1 | 2 | 1 | 1 | 2 | ||||||||||||||||||
CD3+/CD4+ | 1 | 1 | 2 | 1 | ||||||||||||||||||||
CD4+/CD8- | 1 | 1 | 2 | 1 | ||||||||||||||||||||
T helper | CD4+/CD69- | 1 | 2 | 1 | 1 | |||||||||||||||||||
cells | CD4+/CD69+ | |||||||||||||||||||||||
others | CD4+/CD44low | 1 | 1 | 1 | 1 | |||||||||||||||||||
CD4+/CD44high | 1 | 3 | 1 | 1 | 2 | |||||||||||||||||||
CD4+/CD62L- | 2 | 2 | 1 | |||||||||||||||||||||
CD4+/CD62L+ | 2 | 1 | 1 | 2 | ||||||||||||||||||||
CD4+/FoxP3- | 1 | 1 | 1 | 1 | ||||||||||||||||||||
CD4+/IFNγ- | 1 | 1 | 2 | |||||||||||||||||||||
Tregs | CD4+/FoxP3+ | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | |||||||||||||
CD8+/FoxP3+ | 3 | 2 | 2 | 2 | 1 | |||||||||||||||||||
CD3+/CD4- | 1 | 1 | 2 | 2 | ||||||||||||||||||||
others | CD3+/CD8- | 1 | 1 | 2 | ||||||||||||||||||||
CD3+/B220- | 2 | 1 | ||||||||||||||||||||||
CD3+/B220+ | 2 | 1 | 1 | 1 | 1 | |||||||||||||||||||
DCs | PDCA1+/CD86- | 1 | 1 | 1 | ||||||||||||||||||||
PD cells | PDCA1+/CD86+ | 1 | ||||||||||||||||||||||
PDCA1+/CD11c- | ||||||||||||||||||||||||
PDCA1+/CD11c+ | 3 | |||||||||||||||||||||||
CD11c+/CD86- | 1 | 1 | ||||||||||||||||||||||
cDCs | CD11c+/CD86+ | 1 | ||||||||||||||||||||||
CD11c+/PDCA1- | 1 | 2 | 2 |
Overlapping QTLs for Immune Cell Phenotypes and AIP
The significant QTLs for AIP with sex as a covariate are located on chromosomes 2, 4 and 6 (Table 4). Of these, chromosomes 2 and 6 also harbor significant QTLs for B cells, cytotoxic T cells, T helper cells and Tregs. On chromosome 4, we identified QTLs for the same subpopulations, except of Tregs (Table 5). No QTLs for conventional or plasmacytoid DCs are located on these disease-associated chromosomes.
In subsequent analyses, QTL were considered as overlapping when their peaks are no more than 10 Mb apart. Interestingly, for the QTLs AIP s1, AIP s3 and AIP s4 such overlaps with QTLs for individual leukocyte subsets could be observed (Fig 2, Table 6). The peak of QTL AIP s1 on chromosome 2 was next to peaks of QTLs for subtypes of T helper cells (CD4+/CD44high), Tregs (FoxP3+/CD4+, FoxP3+/CD8+) and cytotoxic T cells (CD8+/CD69+, CD8+/CD44high). On chromosome 6, the QTLs AIP s3 and AIP s4 overlapped with QTLs for Tregs (again, FoxP3+/CD8+) and Th17 cells (IL17+/CD4+), respectively.
Table 6. Overlapping QTLs for AIP and leukocyte subtypes with distances between peaks below 10 Mbp.
Cells/QTL (bold) | Phenotype | Chr | Peak (Mbp) | CI (Mbp) | -log10(p) |
---|---|---|---|---|---|
AIP s1 | AIP | 2 | 59.9 | 56.4–73.3 | 4.23 |
T regulatory cells | FoxP3+/CD4+ | 2 | 59.9 | 56.4–73.3 | 7.05 |
T regulatory cells | FoxP3+/CD8+ | 2 | 59.9 | 56.4–61.6 | 6.34 |
Cytotoxic T cells | CD8+/CD69+ | 2 | 65.0 | 65–66.8 | 6.43 |
T helper cells | CD44high/CD4+ | 2 | 68.1 | 59.9–71.4 | 9.62 |
Cytotoxic T cells | CD44high/CD8+ | 2 | 68.1 | 61.6–73.3 | 5.86 |
AIP s3 | AIP | 6 | 104.8 | 94–106.3 | 4.31 |
T regulatory cells | FoxP3+/CD8+ | 6 | 97.9 | 84.8–98.4 | 4.12 |
AIP s4 | AIP | 6 | 116.7 | 109.9–136.3 | 5.54 |
Th17 cells | IL17+/CD4+ | 6 | 125.0 | 125–130.2 | 4.54 |
Detection of CD44 on Lymphocytes in Pancreatic Tissue
CD4+/CD44high lymphocytes were the only leukocyte subtype that could be linked to AIP both by the correlation studies (Table 3) and from observed overlapping QTL (Table 6). We therefore asked if cells with this phenotype were also present in the inflamed pancreatic tissue. Using serial sections, we found that cells expressing CD4 and CD44, respectively, could be detected in overlapping regions of lymphocytic foci (Fig 3).
Discussion
As other autoimmune diseases, AIP is considered to develop after environmental triggering of genetically susceptible individuals [1,15–18,32,33]. Except of a few HLA serotypes and SNP polymorphisms in non-HLA genes, however, no AIP-associated genetic factors have been identified in humans so far. This is largely due to the relative rarity of the disease (estimated prevalence in the general population: <1/100,000), which hampers the buildup of large cohorts of patients.
Employing an autoimmune-prone intercross mouse line, we previously identified five QTLs of murine AIP that may provide additional insights into the pathogenesis of the disease [26]. In our current work, we expanded these investigations by analyzing AIP-associated immune cell phenotypes and their genetic control. Since AIP of the parental MRL/MpJ mouse strain is more frequent in females, sex was considered as a covariate in all our investigations. Taking this approach, we confirmed the susceptibility loci on mouse chromosomes 2 (CI 56.3–81.9 Mb), 4 (CI 81.3–120.7 Mb) and 6 (CI 111.2–133.9 Mb) (Table 4). Since our previous analysis [26] was performed without sex as covariate, these QTLs can now be assigned as sex-independent. Neither here nor in our previous study, we could identify any X-linked QTL, suggesting that the effect of X-linked genes is too small to be verified by our approach. The reason for the higher susceptibility of the female mice to AIP, therefore, remains to be deciphered.
Recently, Okada et al. reported a pathogenetic role of mag, an autoimmune susceptibility locus encoded by the telomeric region of MRL/MpJ mouse chromosome 1, in murine AIP [34]. Interestingly, this susceptibility locus is not preserved in our intercross line since we did not map significant genetic markers on chromosome 1.
In a comprehensive effort, we phenotyped a variety of B cell, T cell and dendritic cell subtypes by determining their relative frequencies in the spleen of G4 mice, and systematically searched for genetic loci that influence these phenotypes. We came up with no less than 273 QTLs that control 37 different splenocyte subtypes (Table 5). This original set of loci was considerably narrowed down when an overlap with one of the AIP QTLs was introduced as an additional criterion: Of the immune cell-associated QTLs, only five overlapped with the QTL AIP s1, and one each with AIP s3 and AIP s4 (Table 6). The corresponding immune cell phenotypes consist of activated cytotoxic T cells (CD8+/CD69+), Th17 cells (CD4+/IL17+), two types of T cells expressing the memory marker CD44 (CD4+/CD44high and CD8+/CD44high), and also two types of regulatory T cells (FoxP3+/CD4+ and FoxP3+/CD8+; with the latter being influenced by two distinct loci).
So far, we had identified a small subset of QTLs that influence both the appearance of AIP and control a total of six different immune cell phenotypes in the spleen. These data, however, did not address the question of a direct association between the two phenotypes (AIP and frequency of the respective immune cells). Therefore, a correlation analysis (Table 2) was performed which revealed a statistically significant negative correlation between AIP and cytotoxic T cells of the phenotype CD8+/CD44low, and a positive such for AIP and activated T helper cells (CD4+/CD69+) as well as CD4+/CD44high cells. For the first two T cell subtypes, no QTLs overlapping with QTLs for AIP had been found. CD4+ cells expressing the memory marker CD44 are therefore the only cell type which could be linked to AIP by both approaches. Both cell surface markers could also be detected on immune cells in pancreatic lesions (Fig 3). The latter findings complement our previous studies regarding the composition of the immune cell infiltrate in MRL/MpJ mice, which had shown a predominance of CD4 cells over CD8 cells infiltrating the pancreas as well as the presence of plasma cells, regulatory T cells and macrophages [13,29].
To the best of our knowledge, this is the first experimental hint for a potential involvement of memory T cells in the pathogenesis of AIP. Apart from AIP, however, memory T cells (and here in particular self-antigen-reactive CD4+ effector memory T cells) have been suggested to drive the progression of autoimmune diseases because of their ready effector functionality and relative longevity [35]. Along these lines, persistent antigen increases the pool of effector memory T cells, which may in turn trigger the progression of the autoimmune disease through the potent production of inflammatory cytokines, such as interferon-γ [36,37]. Indeed, we have previously observed high mRNA levels of this cytokine (as well as of interleukin-2 and interleukin-6) in pancreatic tissue of MRL/Mp mice with advanced AIP and also shown that injections of interferon-γ accelerate and aggravate the disease [12, 29].
Of course, immune cell phenotypes that fulfilled only one criterion (existence of overlapping QTLs with AIP or correlation with the appearance of AIP) may nevertheless be important in the progression of the disease, and their QTLs demand further investigation let alone as a controlling factor in immunity. Thus, activated CD4+ and CD8+ lymphocytes, Th17 cells and Tregs all have already been implicated in the pathogenesis of AIP [reviewed in 1]. Moreover, employing MRL/MpJ mice we have recently shown (based on immunohistochemical studies and a flow cytometric analysis of splenocytes) that the immunosuppressant drug rapamycin significantly reduces pancreatic damage by expanding Tregs of the phenotype CTLA4+/CD4+/FoxP3+ and a subsequent reduction of the effector T cell response [13]. We consider the fact that this part of our observations is in line with previous investigations also as supportive for our novel concept regarding the role of memory T cells in the development of murine AIP.
The overlapping QTL region for AIP and CD4+/CD44high lymphocytes, which is located on chromosome 2 [Table 6], still spans roughly 11 Mb and contains more than 70 genes. Noteworthy, the interval contains the genes Sjogren syndrome antigen B (Ssb) and Ubiquitin protein ligase E3 component n-recognin 3 (Ubr3), which we have previously described as part of the QTL AIP1 [26]. The encoded proteins might be disease-relevant autoantigens and therefore deserve special attention in future studies. A full list of genes in the overlapping QTL region is provided in the S3 Table.
Taken together, we hypothesize that CD4+/CD44high memory T cells play a previously unrecognized role in murine AIP, and suggest that these cells are an important link between genetic susceptibility and development of the disease (Fig 4). Currently, fine-mapping studies are underway to narrow down AIP loci and overlapping QTLs for immune cell phenotypes, and to identify candidate genes that control the respective phenotypes.
Supporting Information
Acknowledgments
We gratefully acknowledge the excellent technical assistance of Mrs Katja Bergmann, Mrs Ilona Klamfuss and Mrs Katrin Sievert-Küchenmeister.
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
Deutsche Forschungsgemeinschaft (DFG; http://www.dfg.de/en/index.jsp), 53170 Bonn, Germany; grants DFG EXC306/1 and IB 24/9-1 to Saleh Ibrahim and JA 819/5-1 to Robert Jaster. The funder had no role in study design, data collection, analysis and interpretation, decision to publish, and preparation of the manuscript.
References
- 1. Hart PA, Zen Y, Chari ST. Recent Advances in Autoimmune Pancreatitis. Gastroenterology. 2015;149: 39–51. 10.1053/j.gastro.2015.03.010 [DOI] [PubMed] [Google Scholar]
- 2. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40: 352–358. 10.1097/MPA.0b013e3182142fd2 [DOI] [PubMed] [Google Scholar]
- 3. Löhr JM, Faissner R, Koczan D, Bewerunge P, Bassi C, Brors B, et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol. 2010;105: 2060–2071. 10.1038/ajg.2010.141 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Aparisi L, Farre A, Gomez-Cambronero L, Martinez J, De Las Heras G, Corts J, et al. Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut. 2005;54: 703–709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Klöppel G, Detlefsen S, Chari ST, Longnecker DS, Zamboni G. Autoimmune pancreatitis: the clinicopathological characteristics of the subtype with granulocytic epithelial lesions. J Gastroenterol. 2010;45: 787–793. 10.1007/s00535-010-0265-x [DOI] [PubMed] [Google Scholar]
- 6. Zhang L, Chari S, Smyrk TC, Deshpande V, Klöppel G, Kojima M, et al. Autoimmune pancreatitis (AIP) type 1 and type 2: an international consensus study on histopathologic diagnostic criteria. Pancreas. 2011;40: 1172–1179. 10.1097/MPA.0b013e318233bec5 [DOI] [PubMed] [Google Scholar]
- 7. Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62: 1607–1615. 10.1136/gutjnl-2012-302886 [DOI] [PubMed] [Google Scholar]
- 8. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology. 2000;118: 573–581. [DOI] [PubMed] [Google Scholar]
- 9. Yamamoto M, Harada S, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. Clinical and pathological differences between Mikulicz's disease and Sjogren's syndrome. Rheumatology (Oxford). 2005;44: 227–234. [DOI] [PubMed] [Google Scholar]
- 10. Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45: 1538–1546. [DOI] [PubMed] [Google Scholar]
- 11. Kanno H, Nose M, Itoh J, Taniguchi Y, Kyogoku M. Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism. Clin Exp Immunol. 1992;89: 68–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Fitzner B, Holzhueter SA, Ibrahim S, Nizze H, Jaster R. Interferon-gamma treatment accelerates and aggravates autoimmune pancreatitis in the MRL/Mp mouse. Pancreatology. 2009;9: 233–239. 10.1159/000199434 [DOI] [PubMed] [Google Scholar]
- 13. Schwaiger T, van den Brandt C, Fitzner B, Zaatreh S, Kraatz F, Dummer A, et al. Autoimmune pancreatitis in MRL/Mp mice is a T-cell mediated disease responsive to cyclosporine A and rapamycin treatment. Gut. 2014;63: 494–505. 10.1136/gutjnl-2012-303635 [DOI] [PubMed] [Google Scholar]
- 14. Miyoshi H, Uchida K, Taniguchi T, Yazumi S, Matsushita M, Takaoka M, et al. Circulating naïve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas. 2008;36: 133–140. 10.1097/MPA.0b013e3181577553 [DOI] [PubMed] [Google Scholar]
- 15. Franke A, Balschun T, Sina C, Ellinghaus D, Häsler R, Mayr G, et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet. 2010;42: 292–294. 10.1038/ng.553 [DOI] [PubMed] [Google Scholar]
- 16. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41: 1234–1237. 10.1038/ng.472 [DOI] [PubMed] [Google Scholar]
- 17. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125: 61–67. [DOI] [PubMed] [Google Scholar]
- 18. Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum. 2010;62: 369–377. 10.1002/art.27272 [DOI] [PubMed] [Google Scholar]
- 19. Kawa S, Ota M, Yoshizawa K, Horiuchi A, Hamano H, Ochi Y, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology. 2002;122: 1264–1269. [DOI] [PubMed] [Google Scholar]
- 20. Park do H, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134: 440–446. [DOI] [PubMed] [Google Scholar]
- 21. Umemura T, Ota M, Hamano H, Katsuyama Y, Muraki T, Arakura N, et al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol. 2008;103: 588–594. 10.1111/j.1572-0241.2007.01750.x [DOI] [PubMed] [Google Scholar]
- 22. Chang MC, Chang YT, Tien YW, Liang PC, Jan IS, Wei SC, et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem. 2007;53: 1700–1705. [DOI] [PubMed] [Google Scholar]
- 23. Chang MC, Jan IS, Liang PC, Jeng YM, Yang CY, Tien YW, et al. Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis. J Gastroenterol Hepatol. 2014;29: 2038–2042. 10.1111/jgh.12649 [DOI] [PubMed] [Google Scholar]
- 24. Umemura T, Ota M, Hamano H, Katsuyama Y, Kiyosawa K, Kawa S. Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut. 2006;55: 1367–1368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Ota M, Ito T, Umemura T, Katsuyama Y, Yoshizawa K, Hamano H, et al. Polymorphism in the KCNA3 gene is associated with susceptibility to autoimmune pancreatitis in the Japanese population. Dis Markers. 2011;31: 223–229. 10.3233/DMA-2011-0820 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Asghari F, Fitzner B, Holzhüter SA, Nizze H, de Castro Marques A, Müller S, et al. Identification of quantitative trait loci for murine autoimmune pancreatitis. J Med Genet. 2011;48: 557–562. 10.1136/jmg.2011.089730 [DOI] [PubMed] [Google Scholar]
- 27. Ranea LM, de Castro Marques A, Möller S, Gupta Y, Ibrahim SM. Genetic control of spontaneous arthritis in a four-way advanced intercross line. PLoS One. 2013;8: e75611 10.1371/journal.pone.0075611 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Ludwig RJ, Müller S, Marques Ad, Recke A, Schmidt E, Zillikens D, et al. Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita. J Invest Dermatol. 2012;132: 1409–1415. 10.1038/jid.2011.466 [DOI] [PubMed] [Google Scholar]
- 29. Sorg H, Lorch B, Jaster R, Fitzner B, Ibrahim S, Holzhueter SA, et al. Early rise in inflammation and microcirculatory disorder determine the development of autoimmune pancreatitis in the MRL/Mp-mouse. Am J Physiol Gastrointest Liver Physiol. 2008;295: G1274–1280. 10.1152/ajpgi.90341.2008 [DOI] [PubMed] [Google Scholar]
- 30. Mott R, Talbot CJ, Turri MG, Collins AC, Flint J. A method for fine mapping quantitative trait loci in outbred animal stocks. Proc Natl Acad Sci U S A. 2000;97: 12649e54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Möller S, Krabbenhöft HN, Tille A, Paleino D, Williams A, Wolstencroft K, et al. Community-driven computational biology with Debian Linux. BMC Bioinformatics. 2010;11(Suppl 12): S5 10.1186/1471-2105-11-S12-S5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382: 819–831. 10.1016/S0140-6736(13)60954-X [DOI] [PubMed] [Google Scholar]
- 33. Emmrich J, Jaster R. Autoimmune diseases in gastroenterology. Curr Pharm Des. 2012;18: 4542–4545. [DOI] [PubMed] [Google Scholar]
- 34. Okada Y, Nakamura T, Ichii O, Otsuka S, Kon Y. Pathogenetic role of an autoimmune susceptibility locus derived from MRL/MpJ strain chromosome 1 in chronic pancreas inflammation. Lupus. 2014;23: 1112–1123. 10.1177/0961203314536249 [DOI] [PubMed] [Google Scholar]
- 35. Devarajan P, Chen Z. Autoimmune effector memory T cells: the bad and the good. Immunol Res. 2013;57: 12–22. 10.1007/s12026-013-8448-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Kawakami N, Odoardi F, Ziemssen T, Bradl M, Ritter T, Neuhaus O, et al. Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. J Immunol. 2005;175: 69–81. [DOI] [PubMed] [Google Scholar]
- 37. Sattler A, Wagner U, Rossol M, Sieper J, Wu P, Krause A, et al. Cytokine-induced human IFN-gamma-secreting effector-memory Th cells in chronic autoimmune inflammation. Blood. 2009;113: 1948–1956. 10.1182/blood-2008-02-139147 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.